Preclinical Pharmacology of Zofenopril, an Inhibitor of Angiotensin I Converting Enzyme

Zofenopril calcium (one-half calcium salt) is a prodrug ester analog of captopril whose biological effects are manifested by its active component, SQ 26,333. Because of the relative insolubilities of both zofenopril calcium and SQ 26,333, zofenopril potassium salt and SQ 26,703, the arginine salt of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cardiovascular pharmacology 1989-06, Vol.13 (6), p.887-894
Hauptverfasser: DeForrest, J M, Waldron, T L, Krapcho, J, Turk, C, Rubin, B, Powell, J R, Cushman, D W, Petrillo, E W
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 894
container_issue 6
container_start_page 887
container_title Journal of cardiovascular pharmacology
container_volume 13
creator DeForrest, J M
Waldron, T L
Krapcho, J
Turk, C
Rubin, B
Powell, J R
Cushman, D W
Petrillo, E W
description Zofenopril calcium (one-half calcium salt) is a prodrug ester analog of captopril whose biological effects are manifested by its active component, SQ 26,333. Because of the relative insolubilities of both zofenopril calcium and SQ 26,333, zofenopril potassium salt and SQ 26,703, the arginine salt of the active ACE (angiotensin I converting enzyme) inhibitory moiety of zofenopril, were employed in many of the following studies. The in vitro and in vivo pharmacological effects of zofenopril have been evaluated and comparisons have been made to captopril. In vitro, SQ 26,703 was more potent than captopril as an inhibitor of rabbit lung ACE (IC50 = 8 vs. 23 nM). SQ 26,703 was also a potent inhibitor of angiotensin I (AI)-induced contractions (EC50 = 3 nM) and a potentiator of bradykinin-induced contractions (EC50 = 1 nM) of isolated guinea pig ileum, while it had no effect on the inotropic effects of angiotensin II, BaCl2, PGE1, histamine, serotonin, or acetycholine in the same tissue, signifying that zofenopril is a specific inhibitor of ACE. In vivo, the potency of SQ 26,703 was equal to or greater than that of captopril as an inhibitor of an AI pressor response when given intravenously to rats, dogs, and monkeys. After oral administration of equimolar doses, zofenopril was the more effective and longer lasting ACE inhibitor in all three species. In SHR, doses of 6.6 and 22.0 mg/kg, p.o. lowered pressure by 20 and 33 mm Hg, respectively, while 30 mg/kg of captopril lowered pressure by 25 mm Hg. Zofenoprilʼs effects were longer lasting. A combination of zofenopril and hydrochlorothiazide lowered pressure more (34 mm Hg) than zofenopril alone (20 mm Hg) in SHR. In two-kidney, one-clip renal hypertensive rats, zofenopril was more effective than captopril as an antihypertensive and again zofenoprilʼs effects lasted longer. In anesthetized dogs, zofenopril had no effect on catecholamine-induced pressor responses or reflex changes in blood pressure and heart rate during head-up tilting or bilateral carotid artery occlusion. It is concluded that zofenopril is an effective and long lasting inhibitor of ACE in rats, dogs, and monkeys and an effective antihypertensive agent in rats.
doi_str_mv 10.1097/00005344-198906000-00011
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79527773</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79527773</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4341-616e0bced403b3c1daec8833fbb14428c19db55cacde858308553fe08f77c6d73</originalsourceid><addsrcrecordid>eNp1kUFv2yAUx9HUqUu7fYRJPlQ9zR0YMPgYRekaqVJ72DRpF4Txc0KLIQWnUfbpS5ostyEh9PT_PdD7gVBB8A3BjfiO8-KUsZI0ssF1rsq8CfmAJoRTWjJc0TM0waTGZcVY_QldpPSUCcZFfY7OKyYZlnSCfj9GMM56a7QrHlc6DtoEF5a7IvTFn9CDD-to3bdC-2LhV7a1Y4j7bOqXNozgk81BMQv-FeJo_bKY-7-7AT6jj712Cb4cz0v063b-c3ZX3j_8WMym96VhlJGyJjXg1kDHMG2pIZ0GIyWlfdsSxippSNO1nBttOpBcUiw5pz1g2Qth6k7QS3R9uHcdw8sG0qgGmww4pz2ETVKi4ZUQgmZQHkATQ0oRepXnGnTcKYLV3qn651SdnKp3p7n16_GNTTtAd2o8Ssz51THXKWvso_bGphMmKtE0FGeMHbBtcCPE9Ow2W4hqBdqNK_W_H6VvWSWOTQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79527773</pqid></control><display><type>article</type><title>Preclinical Pharmacology of Zofenopril, an Inhibitor of Angiotensin I Converting Enzyme</title><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>DeForrest, J M ; Waldron, T L ; Krapcho, J ; Turk, C ; Rubin, B ; Powell, J R ; Cushman, D W ; Petrillo, E W</creator><creatorcontrib>DeForrest, J M ; Waldron, T L ; Krapcho, J ; Turk, C ; Rubin, B ; Powell, J R ; Cushman, D W ; Petrillo, E W</creatorcontrib><description>Zofenopril calcium (one-half calcium salt) is a prodrug ester analog of captopril whose biological effects are manifested by its active component, SQ 26,333. Because of the relative insolubilities of both zofenopril calcium and SQ 26,333, zofenopril potassium salt and SQ 26,703, the arginine salt of the active ACE (angiotensin I converting enzyme) inhibitory moiety of zofenopril, were employed in many of the following studies. The in vitro and in vivo pharmacological effects of zofenopril have been evaluated and comparisons have been made to captopril. In vitro, SQ 26,703 was more potent than captopril as an inhibitor of rabbit lung ACE (IC50 = 8 vs. 23 nM). SQ 26,703 was also a potent inhibitor of angiotensin I (AI)-induced contractions (EC50 = 3 nM) and a potentiator of bradykinin-induced contractions (EC50 = 1 nM) of isolated guinea pig ileum, while it had no effect on the inotropic effects of angiotensin II, BaCl2, PGE1, histamine, serotonin, or acetycholine in the same tissue, signifying that zofenopril is a specific inhibitor of ACE. In vivo, the potency of SQ 26,703 was equal to or greater than that of captopril as an inhibitor of an AI pressor response when given intravenously to rats, dogs, and monkeys. After oral administration of equimolar doses, zofenopril was the more effective and longer lasting ACE inhibitor in all three species. In SHR, doses of 6.6 and 22.0 mg/kg, p.o. lowered pressure by 20 and 33 mm Hg, respectively, while 30 mg/kg of captopril lowered pressure by 25 mm Hg. Zofenoprilʼs effects were longer lasting. A combination of zofenopril and hydrochlorothiazide lowered pressure more (34 mm Hg) than zofenopril alone (20 mm Hg) in SHR. In two-kidney, one-clip renal hypertensive rats, zofenopril was more effective than captopril as an antihypertensive and again zofenoprilʼs effects lasted longer. In anesthetized dogs, zofenopril had no effect on catecholamine-induced pressor responses or reflex changes in blood pressure and heart rate during head-up tilting or bilateral carotid artery occlusion. It is concluded that zofenopril is an effective and long lasting inhibitor of ACE in rats, dogs, and monkeys and an effective antihypertensive agent in rats.</description><identifier>ISSN: 0160-2446</identifier><identifier>EISSN: 1533-4023</identifier><identifier>DOI: 10.1097/00005344-198906000-00011</identifier><identifier>PMID: 2484083</identifier><identifier>CODEN: JCPCDT</identifier><language>eng</language><publisher>Philadelphia, PA: Lippincott-Raven Publishers</publisher><subject>Angiotensin-Converting Enzyme Inhibitors - metabolism ; Animals ; Antihypertensive agents ; Biological and medical sciences ; Biological Availability ; Blood Pressure - drug effects ; Captopril - analogs &amp; derivatives ; Captopril - pharmacokinetics ; Captopril - pharmacology ; Cardiovascular system ; Dogs ; Female ; Ileum ; In Vitro Techniques ; Macaca fascicularis ; Male ; Medical sciences ; Muscle Contraction - drug effects ; Pharmacology. Drug treatments ; Rats</subject><ispartof>Journal of cardiovascular pharmacology, 1989-06, Vol.13 (6), p.887-894</ispartof><rights>Lippincott-Raven Publishers.</rights><rights>1989 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4341-616e0bced403b3c1daec8833fbb14428c19db55cacde858308553fe08f77c6d73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf><![CDATA[$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&PDF=y&D=ovft&AN=00005344-198906000-00011$$EPDF$$P50$$Gwolterskluwer$$H]]></linktopdf><linktohtml>$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;NEWS=n&amp;CSC=Y&amp;PAGE=fulltext&amp;D=ovft&amp;AN=00005344-198906000-00011$$EHTML$$P50$$Gwolterskluwer$$H</linktohtml><link.rule.ids>314,780,784,4608,27923,27924,64565,65332</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=7279930$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2484083$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DeForrest, J M</creatorcontrib><creatorcontrib>Waldron, T L</creatorcontrib><creatorcontrib>Krapcho, J</creatorcontrib><creatorcontrib>Turk, C</creatorcontrib><creatorcontrib>Rubin, B</creatorcontrib><creatorcontrib>Powell, J R</creatorcontrib><creatorcontrib>Cushman, D W</creatorcontrib><creatorcontrib>Petrillo, E W</creatorcontrib><title>Preclinical Pharmacology of Zofenopril, an Inhibitor of Angiotensin I Converting Enzyme</title><title>Journal of cardiovascular pharmacology</title><addtitle>J Cardiovasc Pharmacol</addtitle><description>Zofenopril calcium (one-half calcium salt) is a prodrug ester analog of captopril whose biological effects are manifested by its active component, SQ 26,333. Because of the relative insolubilities of both zofenopril calcium and SQ 26,333, zofenopril potassium salt and SQ 26,703, the arginine salt of the active ACE (angiotensin I converting enzyme) inhibitory moiety of zofenopril, were employed in many of the following studies. The in vitro and in vivo pharmacological effects of zofenopril have been evaluated and comparisons have been made to captopril. In vitro, SQ 26,703 was more potent than captopril as an inhibitor of rabbit lung ACE (IC50 = 8 vs. 23 nM). SQ 26,703 was also a potent inhibitor of angiotensin I (AI)-induced contractions (EC50 = 3 nM) and a potentiator of bradykinin-induced contractions (EC50 = 1 nM) of isolated guinea pig ileum, while it had no effect on the inotropic effects of angiotensin II, BaCl2, PGE1, histamine, serotonin, or acetycholine in the same tissue, signifying that zofenopril is a specific inhibitor of ACE. In vivo, the potency of SQ 26,703 was equal to or greater than that of captopril as an inhibitor of an AI pressor response when given intravenously to rats, dogs, and monkeys. After oral administration of equimolar doses, zofenopril was the more effective and longer lasting ACE inhibitor in all three species. In SHR, doses of 6.6 and 22.0 mg/kg, p.o. lowered pressure by 20 and 33 mm Hg, respectively, while 30 mg/kg of captopril lowered pressure by 25 mm Hg. Zofenoprilʼs effects were longer lasting. A combination of zofenopril and hydrochlorothiazide lowered pressure more (34 mm Hg) than zofenopril alone (20 mm Hg) in SHR. In two-kidney, one-clip renal hypertensive rats, zofenopril was more effective than captopril as an antihypertensive and again zofenoprilʼs effects lasted longer. In anesthetized dogs, zofenopril had no effect on catecholamine-induced pressor responses or reflex changes in blood pressure and heart rate during head-up tilting or bilateral carotid artery occlusion. It is concluded that zofenopril is an effective and long lasting inhibitor of ACE in rats, dogs, and monkeys and an effective antihypertensive agent in rats.</description><subject>Angiotensin-Converting Enzyme Inhibitors - metabolism</subject><subject>Animals</subject><subject>Antihypertensive agents</subject><subject>Biological and medical sciences</subject><subject>Biological Availability</subject><subject>Blood Pressure - drug effects</subject><subject>Captopril - analogs &amp; derivatives</subject><subject>Captopril - pharmacokinetics</subject><subject>Captopril - pharmacology</subject><subject>Cardiovascular system</subject><subject>Dogs</subject><subject>Female</subject><subject>Ileum</subject><subject>In Vitro Techniques</subject><subject>Macaca fascicularis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Muscle Contraction - drug effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Rats</subject><issn>0160-2446</issn><issn>1533-4023</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUFv2yAUx9HUqUu7fYRJPlQ9zR0YMPgYRekaqVJ72DRpF4Txc0KLIQWnUfbpS5ostyEh9PT_PdD7gVBB8A3BjfiO8-KUsZI0ssF1rsq8CfmAJoRTWjJc0TM0waTGZcVY_QldpPSUCcZFfY7OKyYZlnSCfj9GMM56a7QrHlc6DtoEF5a7IvTFn9CDD-to3bdC-2LhV7a1Y4j7bOqXNozgk81BMQv-FeJo_bKY-7-7AT6jj712Cb4cz0v063b-c3ZX3j_8WMym96VhlJGyJjXg1kDHMG2pIZ0GIyWlfdsSxippSNO1nBttOpBcUiw5pz1g2Qth6k7QS3R9uHcdw8sG0qgGmww4pz2ETVKi4ZUQgmZQHkATQ0oRepXnGnTcKYLV3qn651SdnKp3p7n16_GNTTtAd2o8Ssz51THXKWvso_bGphMmKtE0FGeMHbBtcCPE9Ow2W4hqBdqNK_W_H6VvWSWOTQ</recordid><startdate>198906</startdate><enddate>198906</enddate><creator>DeForrest, J M</creator><creator>Waldron, T L</creator><creator>Krapcho, J</creator><creator>Turk, C</creator><creator>Rubin, B</creator><creator>Powell, J R</creator><creator>Cushman, D W</creator><creator>Petrillo, E W</creator><general>Lippincott-Raven Publishers</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198906</creationdate><title>Preclinical Pharmacology of Zofenopril, an Inhibitor of Angiotensin I Converting Enzyme</title><author>DeForrest, J M ; Waldron, T L ; Krapcho, J ; Turk, C ; Rubin, B ; Powell, J R ; Cushman, D W ; Petrillo, E W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4341-616e0bced403b3c1daec8833fbb14428c19db55cacde858308553fe08f77c6d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Angiotensin-Converting Enzyme Inhibitors - metabolism</topic><topic>Animals</topic><topic>Antihypertensive agents</topic><topic>Biological and medical sciences</topic><topic>Biological Availability</topic><topic>Blood Pressure - drug effects</topic><topic>Captopril - analogs &amp; derivatives</topic><topic>Captopril - pharmacokinetics</topic><topic>Captopril - pharmacology</topic><topic>Cardiovascular system</topic><topic>Dogs</topic><topic>Female</topic><topic>Ileum</topic><topic>In Vitro Techniques</topic><topic>Macaca fascicularis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Muscle Contraction - drug effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Rats</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DeForrest, J M</creatorcontrib><creatorcontrib>Waldron, T L</creatorcontrib><creatorcontrib>Krapcho, J</creatorcontrib><creatorcontrib>Turk, C</creatorcontrib><creatorcontrib>Rubin, B</creatorcontrib><creatorcontrib>Powell, J R</creatorcontrib><creatorcontrib>Cushman, D W</creatorcontrib><creatorcontrib>Petrillo, E W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cardiovascular pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DeForrest, J M</au><au>Waldron, T L</au><au>Krapcho, J</au><au>Turk, C</au><au>Rubin, B</au><au>Powell, J R</au><au>Cushman, D W</au><au>Petrillo, E W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preclinical Pharmacology of Zofenopril, an Inhibitor of Angiotensin I Converting Enzyme</atitle><jtitle>Journal of cardiovascular pharmacology</jtitle><addtitle>J Cardiovasc Pharmacol</addtitle><date>1989-06</date><risdate>1989</risdate><volume>13</volume><issue>6</issue><spage>887</spage><epage>894</epage><pages>887-894</pages><issn>0160-2446</issn><eissn>1533-4023</eissn><coden>JCPCDT</coden><abstract>Zofenopril calcium (one-half calcium salt) is a prodrug ester analog of captopril whose biological effects are manifested by its active component, SQ 26,333. Because of the relative insolubilities of both zofenopril calcium and SQ 26,333, zofenopril potassium salt and SQ 26,703, the arginine salt of the active ACE (angiotensin I converting enzyme) inhibitory moiety of zofenopril, were employed in many of the following studies. The in vitro and in vivo pharmacological effects of zofenopril have been evaluated and comparisons have been made to captopril. In vitro, SQ 26,703 was more potent than captopril as an inhibitor of rabbit lung ACE (IC50 = 8 vs. 23 nM). SQ 26,703 was also a potent inhibitor of angiotensin I (AI)-induced contractions (EC50 = 3 nM) and a potentiator of bradykinin-induced contractions (EC50 = 1 nM) of isolated guinea pig ileum, while it had no effect on the inotropic effects of angiotensin II, BaCl2, PGE1, histamine, serotonin, or acetycholine in the same tissue, signifying that zofenopril is a specific inhibitor of ACE. In vivo, the potency of SQ 26,703 was equal to or greater than that of captopril as an inhibitor of an AI pressor response when given intravenously to rats, dogs, and monkeys. After oral administration of equimolar doses, zofenopril was the more effective and longer lasting ACE inhibitor in all three species. In SHR, doses of 6.6 and 22.0 mg/kg, p.o. lowered pressure by 20 and 33 mm Hg, respectively, while 30 mg/kg of captopril lowered pressure by 25 mm Hg. Zofenoprilʼs effects were longer lasting. A combination of zofenopril and hydrochlorothiazide lowered pressure more (34 mm Hg) than zofenopril alone (20 mm Hg) in SHR. In two-kidney, one-clip renal hypertensive rats, zofenopril was more effective than captopril as an antihypertensive and again zofenoprilʼs effects lasted longer. In anesthetized dogs, zofenopril had no effect on catecholamine-induced pressor responses or reflex changes in blood pressure and heart rate during head-up tilting or bilateral carotid artery occlusion. It is concluded that zofenopril is an effective and long lasting inhibitor of ACE in rats, dogs, and monkeys and an effective antihypertensive agent in rats.</abstract><cop>Philadelphia, PA</cop><cop>Hagerstown, MD</cop><pub>Lippincott-Raven Publishers</pub><pmid>2484083</pmid><doi>10.1097/00005344-198906000-00011</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0160-2446
ispartof Journal of cardiovascular pharmacology, 1989-06, Vol.13 (6), p.887-894
issn 0160-2446
1533-4023
language eng
recordid cdi_proquest_miscellaneous_79527773
source MEDLINE; Journals@Ovid LWW Legacy Archive; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals
subjects Angiotensin-Converting Enzyme Inhibitors - metabolism
Animals
Antihypertensive agents
Biological and medical sciences
Biological Availability
Blood Pressure - drug effects
Captopril - analogs & derivatives
Captopril - pharmacokinetics
Captopril - pharmacology
Cardiovascular system
Dogs
Female
Ileum
In Vitro Techniques
Macaca fascicularis
Male
Medical sciences
Muscle Contraction - drug effects
Pharmacology. Drug treatments
Rats
title Preclinical Pharmacology of Zofenopril, an Inhibitor of Angiotensin I Converting Enzyme
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T12%3A44%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preclinical%20Pharmacology%20of%20Zofenopril,%20an%20Inhibitor%20of%20Angiotensin%20I%20Converting%20Enzyme&rft.jtitle=Journal%20of%20cardiovascular%20pharmacology&rft.au=DeForrest,%20J%20M&rft.date=1989-06&rft.volume=13&rft.issue=6&rft.spage=887&rft.epage=894&rft.pages=887-894&rft.issn=0160-2446&rft.eissn=1533-4023&rft.coden=JCPCDT&rft_id=info:doi/10.1097/00005344-198906000-00011&rft_dat=%3Cproquest_cross%3E79527773%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79527773&rft_id=info:pmid/2484083&rfr_iscdi=true